SAN DIEGO - Genetic analyses suggest that prostate cancer is distinctly different in African-American men compared with European-American men, according to researchers at the National Cancer Institute (NCI) in Bethesda, Md.

PROSTATE BIOPSIES in men with a PSA level of 4.01-10.0 ng/mL and normal findings on digital rectal examination (DRE) should include lateral cores in addition to the sextant biopsy, according to investigators.

SAN FRANCISCO—High exposure to aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is asso-ciated with decreased prostate cancer-specific mortality, according to study findings presented here at the 2008 Genitourinary Cancers Symposium.

SAN FRANCISCO—A PSA velocity (PSAV) threshold of 0.4 ng/mL per year can distinguish between clinically significant and insignificant prostate cancer, new data suggest.

SAN FRANCISCO—Few elderly men with localized prostate cancer will die from the malignancy after 10 years even in treatment is delayed, so active surveillance for these patients may be a reasonable option, according to researchers.

SAN FRANCISCO—Adding thalidomide and bevacizumab to docetaxel may hold promise for treating patients with metastatic androgen-independent prostate cancer (AIPC), investigators report.

Following an initial PSA test result of 3.0-19.99 ng/mL in men aged 50-70 years, a repeat PSA test within seven weeks allows for more accurate assessment as to whether a biopsy will reveal prostate cancer, a British team reports.

INTERMITTENT chemotherapy may be an option for some men with androgen-independent prostate cancer (AIPC), researchers found.

ACTIVATION OF the androgen receptor (AR) appears to promote the invasiveness of both androgen-dependent and androgen-refractory prostate cancer, data suggest.

SAN FRANCISCO—Men recently diagnosed with prostate cancer are at elevated risk of cardiovascular death and suicide, according to separate analyses of a cohort of Swedish men.